Latest1 information on COVID-19
©2022 Stanford Medicine
Trial ID: NCT04927975
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo
- Clinical diagnosis of non-segmental vitiligo (NSV) and no segmental or localized
- Participants with all of the following at Screening and Baseline.
- Visits: ≥ 0.5 F-VASI and ≥ 5 total vitiligo area scoring index (T-VASI).
- Participants who have had prior exposure to immunomodulatory biologic therapy,
for any indications, but discontinued the biologic therapy prior to the first
dose of study drug. Recommended washout periods for biologic therapies include ≥
4 weeks for etanercept; ≥ 8 weeks for adalimumab, infliximab, certolizumab,
golimumab, abatacept, tocilizumab, and ixekizumab; ≥ 16 weeks for secukinumab;
and ≥ 12 weeks for ustekinumab. For biologic therapies not specified, therapies
must be discontinued at least 5 times the mean terminal elimination half-life of
a drug or 3 months prior to Baseline, whichever is longer.
- Participants with segmental or localized vitiligo.
- Participants with other skin conditions that would interfere with evaluation of
vitiligo, participants with uncontrolled thyroid disease, and participants with > 33%
leukotrichia on the face or > 33% leukotrichia on the body (including face).
- Participants previously treated with any topical or systemic janus kinase (JAK)
inhibitor or permanent skin bleaching agents.
- Participants treated with any systemic vitiligo therapy (e.g., methotrexate,
mycophenolate mofetil, corticosteroids), supplemental vitiligo therapy
(antioxidants/vitamins/herbal medicine/traditional Chinese medicine), and/or topical
vitiligo therapy including permanent or temporary tattoos within a minimum of 30 days
prior to the first dose of study drug (Note: Camouflage and makeup may be used).
- Participants treated with any phototherapy, including excimer (or other forms of laser
therapy), within a minimum of 12 weeks prior to the first dose of study drug.
- Participants have history of malignancy other than successfully treated non-melanoma
skin cancer (NMSC) or localized carcinoma in situ of the cervix.
- Recent (within past 6 months) cerebrovascular accident, myocardial infarction,
coronary stenting, and aorto-coronary bypass surgery;
- History of an organ transplant which requires continued immunosuppression;
- History of gastrointestinal (GI) perforation (other than due to appendicitis or
mechanical injury), diverticulitis, or significantly increased risk for GI perforation
per investigator judgment;
- Conditions that could interfere with drug absorption including but not limited to
short bowel syndrome or gastric bypass surgery; subjects with a history of gastric
banding/segmentation are not excluded;
- Uncontrolled thyroid disease;
School of Medicine
300 Pasteur Drive
Stanford, CA 94305